Activated protein C for severe sepsis [1]

New England Journal of Medicine

Volumn 347, Issue 13, 2002, Pages 1035-1036

  Ely, E Wesley ^a   Bernard, Gordon R ^a   Vincent, Jean Louis ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN;

BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LETTER; PRIORITY JOURNAL; SEPSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DRUG APPROVAL; HUMANS; INTRACRANIAL HEMORRHAGES; PROTEIN C; RECOMBINANT PROTEINS; RISK; SEPSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037179678     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200209263471315     Document Type: Letter

References (3)

1. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-30.
2. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002;347:1030-4.
3. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.